SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 77763.91
261.79 (0.34%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
91	Dr. Agarwals Health Care Ltd.	Q V PT	15,099 Small Cap	479.65 (0.69%)	113.37	7.45	26.38	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
92	Fortis Healthcare Ltd.	Q V+ PT	73,605 Mid Cap	974.70 (-0.03%)	319.55	7.98	15.55	-22.45	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
93	Fischer Medical Ventures Ltd.	Q V PT	2,558 Small Cap	39.31 (0.59%)	N/A	8.19	96.10	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
94	Senores Pharmaceuticals Ltd.	Q V+ PT	6,152 Small Cap	1,380.20 (3.32%)	303.81	8.2	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
95	Kwality Pharmaceuticals Ltd.	Q V+ PT	2,827 Small Cap	2,676 (-1.77%)	41.97	8.5	21.70	37.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
96	Rainbow Childrens Medicare Ltd.	Q V PT	14,449 Small Cap	1,439.45 (1.18%)	57.79	8.55	15.91	24.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
97	Krishna Institute of Medical Sciences Ltd	Q V PT	35,098 Small Cap	850.75 (1.81%)	134.63	8.93	11.87	17.04	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
98	Narayana Hrudayalaya Ltd.	Q V PT	40,571 Mid Cap	2,001.90 (0.84%)	50.36	8.94	11.88	45.85	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
99	Aster DM Healthcare Ltd.	Q V+ PT	40,963 Mid Cap	792.70 (0.27%)	105.54	8.95	-13.71	0.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
100	Global Health Ltd.	Q V PT	36,177 Small Cap	1,349.60 (0.30%)	72.91	9	16.83	34.86	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
101	JB Chemicals & Pharmaceuticals Ltd.	Q V+ PT	37,225 Small Cap	2,363.25 (1.93%)	55.22	9.22	15.51	9.89	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
102	Ajanta Pharma Ltd.	Q V+ PT	41,776 Mid Cap	3,325.75 (-0.54%)	39.56	9.23	13.54	10.92	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
103	Emcure Pharmaceuticals Ltd.	Q V PT	35,178 Small Cap	1,837.10 (-0.94%)	47.99	9.48	13.02	9.98	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
104	Max Healthcare Institute Ltd.	Q V+ PT	1,09,728 Mid Cap	1,153.15 (2.28%)	76.07	10.21	46.01	60.18	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
105	Sanofi India Ltd.	Q V PT	8,006 Small Cap	3,426.05 (-1.44%)	25.84	10.26	-8.74	-7.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
106	Sai Life Sciences Ltd.	Q V+ PT	26,284 Small Cap	1,256 (1.44%)	76.97	10.48	17.75	11.20	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
107	Divis Laboratories Ltd.	Q V PT	1,77,179 Large Cap	6,760.55 (1.29%)	69	10.57	11.65	10.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
108	Abbott India Ltd.	Q V PT	54,657 Mid Cap	25,850.45 (0.50%)	35.22	11.45	9.38	18.78	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
109	Dr. Lal Pathlabs Ltd.	Q V PT	27,697 Small Cap	1,646.15 (-0.37%)	54.5	11.51	12.18	13.26	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
110	Panacea Biotec Ltd.	Q V+ PT	3,353 Small Cap	549.60 (0.41%)	N/A	11.75	-8.75	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
111	Apollo Hospitals Enterprise Ltd.	Q V+ PT	1,25,057 Large Cap	8,897.35 (2.30%)	83.78	12.55	-3.49	29.94	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
112	Neuland Laboratories Ltd.	Q V+ PT	24,354 Small Cap	18,916.45 (-0.35%)	67.07	13.06	14.13	64.99	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
113	Anthem Biosciences Ltd.	Q V PT	43,454 Mid Cap	769.70 (-0.21%)	64.8	13.64	23.81	40.64	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
114	Park Medi World Ltd.	Q V+ PT	12,442 Small Cap	294.30 (2.17%)	339.79	14.47	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
115	Gujarat Themis Biosyn Ltd.	Q V+ PT	4,313 Small Cap	386.30 (-2.40%)	92.39	14.99	12.12	15.55	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
116	Vijaya Diagnostic Centre Ltd.	Q V+ PT	14,395 Small Cap	1,364.80 (-2.44%)	83.22	15.04	15.00	18.43	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
117	Thyrocare Technologies Ltd.	Q V+ PT	8,863 Small Cap	554.90 (-0.35%)	54.24	15.31	10.88	8.62	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
118	Laurus Labs Ltd.	Q V+ PT	82,399 Mid Cap	1,541.75 (1.09%)	92.71	15.62	7.19	-2.25	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
119	CORONA Remedies Ltd.	Q V+ PT	12,287 Small Cap	2,036.15 (1.35%)	66.47	16.47	19.49	18.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
120	Rubicon Research Ltd.	Q V+ PT	22,733 Small Cap	1,302.75 (-5.22%)	120.81	16.8	32.49	25.95	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Suven Life Sciences	327.55	9.68%
Shree Ganesh Remed.	673.90	4.90%
Piramal Pharma	175.90	4.58%
Dishman Carbogen Amc	196.60	4.57%
Kopran	194.55	4.07%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Rubicon Research	1,302.75	-5.22%
IOL Chem & Pharma	143.05	-4.76%
Bliss GVS Pharma	506.15	-3.87%
Poly Medicure	1,680.05	-3.32%
3B Blackbio Dx	1,172.50	-2.92%

News about Top Pharma Companies in India

Jul, 2026

USFDA completes unannounced inspection at Rubicon Research’s Pithampur facility

Upon conclusion of the inspection, a Form 483 containing 2 observations was issued to the company

Jul, 2026

Ajanta Pharma informs about disclosures

Ajanta Pharma has informed that the Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CTL Trusteeship.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Senores Pharmaceuticals informs about newspaper publication

Pursuant to Regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Senores Pharmaceuticals has enclosed copies of Newspaper Publications as published, in Financial Express -English and Gujarati Edition, on July 03, 2026, regarding completion of dispatch of Notice of Postal Ballot, intimation of e-voting and other related information. This intimation is also being uploaded on the website of the Company i.e. www.senorespharma.com.

The above information is a part of company's filings submitted to BSE.

Jul, 2026

Ajanta Pharma informs about disclosure

Ajanta Pharma has informed that the exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 03, 2026 for Aayush Agrawal Trust & Aayush Agrawal.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Emcure Pharmaceuticals informs about acquisition

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘LODR Regulations’) and in furtherance to the disclosure made in the Prospectus filed with the Securities Exchange Board of India, during the Initial Public Offer of the Company, Emcure Pharmaceuticals has informed that Marcan Pharmaceuticals Inc., a subsidiary of the Company (‘Marcan’) has on July 02, 2026 (EDT) entered into share purchase agreements with certain shareholders of Mantra Pharma Inc., a step-down subsidiary of the Company (‘Mantra’), to acquire all of Class E Special Shares in the share capital of Mantra. Consequently, Mantra continues to be 100% subsidiary of Marcan. The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the LODR Regulations are provided in Annexure A, enclosed.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Dr. Lal PathLabs informs about newspaper publication

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Dr. Lal PathLabs has attached the copy of newspaper advertisement(s), published in Financial Express and Jansatta on July 02, 2026, intimating about the dispatch of Notice of 32nd Annual General Meeting and Annual Report for FY 2025-26 to the Members of the Company.

The above information is a part of company’s filings submitted to BSE.

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	KMC Speciality Hospitals (India) Ltd.	2,179 Crore
2	Nectar Lifesciences Ltd.	230 Crore
3	Dishman Carbogen Amcis Ltd.	2,948 Crore
4	Unichem Laboratories Ltd.	3,263 Crore
5	Shalby Ltd.	1,873 Crore
6	Lincoln Pharmaceuticals Ltd.	1,253 Crore
7	Natco Pharma Ltd.	16,725 Crore
8	Fabtech Technologies Ltd.	719 Crore
9	Sigachi Industries Ltd.	879 Crore
10	Krsnaa Diagnostics Ltd.	1,857 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	25,850	54,657	35.22	11.45	24.04	35.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,766	1,57,804	72.94	18.81	38.40	29.04
Ajanta Pharma Ltd. (M)	Very Good	3,326	41,776	39.56	9.23	26.73	25.35
Lupin Ltd. (M)	Somewhat Good	2,476	1,09,676	20.57	4.89	11.90	20.83
Zydus Lifesciences Ltd. (M)	Very Good	1,141	1,09,691	21.76	4.22	13.36	20.74

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,542	82,399	103
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,363	37,225	44.17
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,766	1,57,804	42.84
Aurobindo Pharma Ltd. (M)	Very Good	1,620	89,762	40.20
Gland Pharma Ltd. (S)	Very Good	2,461	40,341	31.30
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,363	37,225	55.22	9.22	33.44	15.51
Mankind Pharma Ltd. (M)	Very Good	2,531	1,02,729	50.42	6.27	31.67	14.65
Ajanta Pharma Ltd. (M)	Very Good	3,326	41,776	39.56	9.23	26.73	13.54
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,375	1,12,368	26.78	2.98	14.95	12.09
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,766	1,57,804	72.94	18.81	38.40	11.80

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Zydus Lifesciences Ltd. (M)	Very Good	1,141	1,09,691	21.76	4.22	13.36	30.57
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,905	4,49,048	39.12	5.37	22.41	23.50
Abbott India Ltd. (M)	Very Good	25,850	54,657	35.22	11.45	24.04	18.78
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,375	1,12,368	26.78	2.98	14.95	15.75
Glenmark Pharmaceuticals Ltd. (M)	Very Good	2,210	61,943	45.48	5.89	12.07	14.41

You have 5 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

USFDA completes unannounced inspection at Rubicon Research’s Pithampur facility

Ajanta Pharma informs about disclosures

Senores Pharmaceuticals informs about newspaper publication

Ajanta Pharma informs about disclosure

Emcure Pharmaceuticals informs about acquisition

Dr. Lal PathLabs informs about newspaper publication

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.